232 related articles for article (PubMed ID: 38650316)
1. Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants).
Cochran WV; Dioverti MV; Langlee J; Barker LN; Shedeck A; Toman LP; Avery RK
Ann Transplant; 2024 Apr; 29():e941185. PubMed ID: 38650316
[TBL] [Abstract][Full Text] [Related]
2. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
Valencia Deray KG; Danziger-Isakov LA; Downes KJ
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
4. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
5. [Update on the management of cytomegalovirus infection in transplant recipients].
Neofytos D; Van Delden C; Manuel O
Rev Med Suisse; 2023 Apr; 19(822):726-730. PubMed ID: 37057854
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients.
Saullo JL; Miller RA
Annu Rev Med; 2023 Jan; 74():89-105. PubMed ID: 36332639
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
Haidar G; Boeckh M; Singh N
J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
[TBL] [Abstract][Full Text] [Related]
8. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
Koval CE
Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
[TBL] [Abstract][Full Text] [Related]
9. The next frontier: cytomegalovirus antiviral stewardship programs in solid organ transplant.
Kleiboeker HL; Saddler CM; Jorgenson MR
Curr Opin Infect Dis; 2023 Dec; 36(6):497-504. PubMed ID: 37815319
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
[TBL] [Abstract][Full Text] [Related]
11. Human cytomegalovirus: a survey of end-organ diseases and diagnostic challenges in solid organ transplant recipients.
Contreras G; Ho D
Curr Opin Organ Transplant; 2022 Aug; 27(4):243-249. PubMed ID: 36354249
[TBL] [Abstract][Full Text] [Related]
12. Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review.
Aguado JM; Navarro D; Montoto C; Yébenes M; de Castro-Orós I
Transplant Rev (Orlando); 2024 Jan; 38(1):100804. PubMed ID: 37949797
[TBL] [Abstract][Full Text] [Related]
13. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management.
Khawaja F; Batista MV; El Haddad L; Chemaly RF
Curr Opin Infect Dis; 2019 Dec; 32(6):565-574. PubMed ID: 31567572
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
15. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity.
Manuel O; Avery RK
Curr Opin Infect Dis; 2021 Aug; 34(4):307-313. PubMed ID: 34074879
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation.
Grossi PA; Kamar N; Saliba F; Baldanti F; Aguado JM; Gottlieb J; Banas B; Potena L
Transpl Int; 2022; 35():10332. PubMed ID: 35812158
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation.
Ekenberg C; da Cunha-Bang C; Lodding IP; Sørensen SS; Sengeløv H; Perch M; Rasmussen A; Gustafsson F; Wareham NE; Kirkby N; Kjaer J; Helleberg M; Reekie J; Lundgren JD
Transpl Infect Dis; 2020 Apr; 22(2):e13252. PubMed ID: 31997565
[TBL] [Abstract][Full Text] [Related]
18. Antiviral treatment of cytomegalovirus infection.
Ahmed A
Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
20. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.
Girmenia C; Lazzarotto T; Bonifazi F; Patriarca F; Irrera G; Ciceri F; Aversa F; Citterio F; Cillo U; Cozzi E; Gringeri E; Baldanti F; Cavallo R; Clerici P; Barosi G; Grossi P
Clin Transplant; 2019 Oct; 33(10):e13666. PubMed ID: 31310687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
